尿路基因制药 URGN
$24.75 −$0.98 (-3.81%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $24.00 -3.03%
开盘$25.83
昨收$25.73
当日区间$24.40 – $26.34
成交量1.76M
市值$1.21B
市盈率（TTM）–
股息率–
股权结构与仓位
谁在持有、谁在做空，以及大资金的流向
机构持股比例98.3%-1.14 个百分点，较上季度
持仓机构数235+7 ，较上季度
内部人近期交易31次买入 / 19次卖出净买入
空头持仓比例11.47% 占流通股回补天数 4.9 · 截至 15 Oct 2026
卖空成交量占比13.4%近5日成交量平均占比
卖空成交量占当日成交量比例
大单净流入，近20个交易日
大单买入减卖出的净额（美元）。该窗口期内：+$4.25M（7个净流入日，13个净流出日）。
按单量净流入，近20个交易日
超大单/大单近似机构级别交易；中单/小单近似散户级别交易。各档买入减卖出净额，按窗口期累计。
已披露的前五大股东合计持有32.7%的流通股。
最大股东
按投资者类型
过去6次双周报告中（31 Jul 2026至15 Oct 2026），空头持仓占流通股比例已从9.42%升至11.47%。
近期机构持仓变动
| 股东 | 类型 | 期间 | 持股变动 | 新持股比例 |
|---|---|---|---|---|
| Calamos Investments LLC | Mutual Fund | 2026/Q3 | +97,953 | 0.2% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +87,557 | 0.2% |
| Point72 Asset Management, L.P. | Hedge Fund | 2026/Q3 | +1,525,549 | 3.1% |
| Candriam, Société En Commandite Par Actions | Mutual Fund | 2026/Q3 | +1,065,939 | 2.2% |
| The Toronto-Dominion Bank | Public Company | 2026/Q3 | +753,243 | 6.9% |
| SG Americas Securities, LLC | Private Company | 2026/Q3 | +395,060 | 4.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +355,894 | 6.5% |
| Bank of America Corporation | Public Company | 2026/Q3 | +341,093 | 1.0% |
| Frontier Capital Management | Mutual Fund | 2026/Q3 | +194,435 | 3.1% |
| Kynam Capital Management, LP | Hedge Fund | 2026/Q3 | +186,814 | 5.0% |
| The Goldman Sachs Group, Inc. | Public Company | 2026/Q3 | +175,336 | 1.4% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +128,895 | 2.1% |
| D. E. Shaw & Co., L.P. | Hedge Fund | 2026/Q3 | +122,660 | 2.3% |
| Soleus Capital Management, L.P. | Hedge Fund | 2026/Q3 | +102,810 | 1.7% |
| Hennion & Walsh Asset Management, Inc. | Mutual Fund | 2026/Q3 | +93,192 | 0.6% |
按报告期列出的机构买卖动态，变动幅度从大到小排列。
内部人交易
| 日期 | 内部人 | 职位 | 交易类型 | 股数 | 价格 | 交易后持股 |
|---|---|---|---|---|---|---|
| 7 Oct 2026 | Christopher Degnan | Chief Financial Officer | Derivative Exercise and Sale | -2,202 | $36.69 | 4,561 |
| 7 Oct 2026 | Christopher Degnan | Chief Financial Officer | Derivative Exercise and Retained | +2,281 | – | 4,561 |
| 7 Sep 2026 | Mark Schoenberg | Chief Medical Officer | Intent to Sell (Form 144) | -871 | $44.09 | – |
| 7 Sep 2026 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Intent to Sell (Form 144) | -1,519 | $44.09 | – |
| 7 Sep 2026 | Mark Schoenberg | Chief Medical Officer | Derivative Exercise and Sale | -871 | $42.92 | 59,882 |
| 7 Sep 2026 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Derivative Exercise and Sale | -1,519 | $42.54 | 53,141 |
| 6 Sep 2026 | Mark Schoenberg | Chief Medical Officer | Derivative Exercise and Retained | +796 | – | 59,882 |
| 6 Sep 2026 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Derivative Exercise and Retained | +1,815 | – | 53,141 |
| 25 Aug 2026 | James Robinson | Independent Director | Derivative Exercise and Retained | +2,000 | – | 8,000 |
| 19 Aug 2026 | Mark Schoenberg | Chief Medical Officer | Open Market Disposition | -60,677 | $47.05 | 59,086 |
| 8 Jul 2026 | Mark Schoenberg | Chief Medical Officer | Automatic Disposition | -10,000 | $40.00 | 119,763 |
| 21 Jun 2026 | Cynthia Butitta | Independent Director | Other Derivative Acquisition | +8,000 | – | 8,000 |
| 21 Jun 2026 | Cynthia Butitta | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 | 10,000 |
| 21 Jun 2026 | Stuart Holden | Independent Director | Other Derivative Acquisition | +20,000 | $34.99 | 20,000 |
| 21 Jun 2026 | Arie Belldegrun | Independent Chairperson | Other Derivative Acquisition | +20,000 | $34.99 | 20,000 |
| 21 Jun 2026 | Daniel Wildman | Independent Director | Other Derivative Acquisition | +8,000 | – | 8,000 |
| 21 Jun 2026 | Daniel Wildman | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 | 10,000 |
| 21 Jun 2026 | Mark Schoenberg | Chief Medical Officer | Automatic Disposition | -10,000 | $35.01 | 129,763 |
| 21 Jun 2026 | James Robinson | Independent Director | Other Derivative Acquisition | +8,000 | – | 8,000 |
| 21 Jun 2026 | James Robinson | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 | 10,000 |
数据来自Form 4/Form 144申报文件。负数为减持（出售、赠予或代扣税款股份），正数为增持。
空头持仓（按报告期）
| 报告日期 | 空头股数 | 占流通股比例 | 回补天数 |
|---|---|---|---|
| 15 Oct 2026 | 5,607,261 | 11.5% | 4.9 |
| 30 Sep 2026 | 7,766,918 | 15.9% | 9.9 |
| 15 Sep 2026 | 6,247,498 | 12.8% | 9.2 |
| 31 Aug 2026 | 6,245,387 | 12.8% | 6.8 |
| 14 Aug 2026 | 5,120,407 | 10.5% | 4.8 |
| 31 Jul 2026 | 4,589,109 | 9.4% | 6.6 |
暂无评论——快来第一个聊聊 URGN。
登录后参与讨论。